From cell signaling at the membrane to the nucleus, bringing proteins closely together is often sufficient to activate function. We develop small molecules that induce new protein-protein interactions to reprogram cellular signaling and unlock novel therapeutic strategies.

Most small molecule cancer therapies center on silencing cancer-driving proteins, but they fail to effectively destroy tumors. We take inspiration from the success of immunotherapy and develop molecules that directly, potently, and specifically activate cancer cell death.

Deregulated gene expression is at the heart of tumor formation. However, transcription factors, the effectors of gene regulation, have long eluded drug discovery. We develop molecules that use the principle of induced proximity to engender oncogenic transcription factors with neomorphic activities and induce therapetic gene programs.